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Abstract
Background/Aims: Little research effort has so far been ded-
icated to the analysis of the hypothalamic-pituitary-adrenal 
axis of aetiologically differing subgroups of patients with 
panic disorder (PD). The current study aimed at a deeper un-
derstanding of the cortisol stress response in cannabis-in-
duced PD (CIPD) patients. Methods: Matched groups of 7 PD 
patients (mean age ± SD: 32.95 ± 9.04 years), 7 CIPD patients 
(31.94 ± 8.40 years), and 7 healthy controls (HC) (31.13 ± 8.57 
years) were included in the study. The Trier Social Stress Test 
(TSST) was used for stress induction. Salivary cortisol sam-
ples were collected and panic- and depression-related ques-
tionnaires were applied. Results: A stress response to the 
TSST was found in 28.6% of PD patients, in 51.1% of CIPD 
patients, and in 100% of HC subjects. Statistical analyses re-
vealed a cortisol hyporesponsiveness in PD and CIPD pa-
tients. While cortisol values of PD patients and HC partici-
pants differed significantly, CIPD patients’ cortisol courses 
balanced between those of PD patients and HC subjects. 
Conclusions: Current findings show a distinctive pattern of 
the stress-induced cortisol reaction in CIPD patients, which 
is markedly different from the hormonal response in PD pa-
tients as well as HC subjects. Previous findings of cortisol hy-
poresponsiveness in PD patients compared to HC subjects 
were confirmed. © 2019 S. Karger AG, Basel
Introduction
Panic disorder (PD) is characterized by recurrent and 
sudden episodes of panic attacks which result in behav-
ioural changes up to avoidance behaviour as well as con-
stant concern of future attacks (DSM-IV) [1]. PD with or 
without agoraphobia is a relatively common disease as the 
12-month prevalence rates range up to 2.0% of the Ger-
man adult population [2]. PD correlates with secondary 
comorbid diseases such as depression and substance 
abuse [3]. The connection between substance abuse and 
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anxiety including PDs is bidirectional. Therefore, PD and 
substance use frequently co-occur, and usage of drugs 
and alcohol poses a risk factor for the development of PD. 
Cannabis use was proven to be significantly linked to the 
development of anxiety disorders including PD [4].
On a psychoneuroendocrine level, disease-specific 
physiological alterations of the hypothalamic-pituitary-
adrenal (HPA) axis activity in patients with PD have been 
confirmed to be co-responsible for the pathogenesis of 
PD [5–7]. Clear evidence for hypocortisolism expressed 
in a blunted cortisol responsiveness to stressors has been 
replicated for PD several times [8–10]. A comorbid de-
pressive disorder causes a slight, non-significant increase 
in cortisol levels of patients with PD following stress in-
duction. However, cortisol reactivity of PD patients with 
comorbid depression still runs clearly below that of 
healthy people [8].
 Substance consumption also influences the HPA axis 
activity [11]. The way in which substance consumption 
influences HPA axis activity depends on many factors 
such as type and amount of substances, duration of con-
sumption or degree of dependency. Considerable re-
search effort has focused on examining the consequences 
of cannabis consumption, as it poses a widespread and 
serious public health problem [12]. With regard to psy-
choneuroendocrine effects, evidence concerning the in-
fluence of cannabis use on HPA axis activity remains in-
conclusive. Results from cannabis usage showed signifi-
cantly elevated baseline cortisol levels [13, 14]. However, 
frequent cannabis consumers also displayed a blunted 
cortisol response to delta-9-tetrahydrocannabinol (Δ9-
THC) compared to healthy control (HC) persons, indi-
cating the development of tolerance to the neuroendo-
crine effects of cannabis [14]. After a psychosocial stress 
test, cannabis users showed significantly lower cortisol 
responses than abstainers [15]. Apparently, dosage, fre-
quency of consumed cannabis, and study design seem to 
explain the differences in the results and the impact on 
neuroendocrine processes.
To our knowledge, no research has yet been published 
on PD patients, whose first panic attack was cannabis-
induced regarding their HPA axis reactivity compared to 
“regular” PD patients. On the one hand, in previous in-
vestigations, PD patients showed hypocortisolism as a re-
action to psychosocial stress induction [16]. Cannabis us-
ers also showed significantly lower cortisol responses 
than abstainers in a psychosocial stress test [15]. On the 
other hand, in preclinical studies, the acute administra-
tion of Δ9-THC is associated with an increase in cortisol 
levels [17]. Therefore, it can be proposed that the HPA 
axis reactivity in patients with cannabis-induced panic 
disorder (CIPD) shows hypocortisolism under standard-
ized psychosocial stressor induction compared to healthy 
individuals. However, compared to “regular” PD pa-
tients, the cortisol reactivity in patients with CIPD might 
be higher under standardized psychosocial stressor in-
duction. 
Methods
Study Participants
Patients with PD were tested at the Carl Gustav Carus Univer-
sity Hospital of the Technische Universität Dresden, Germany. Di-
agnoses of patients were confirmed using the Structured Clinical 
Interview (SCID) [18] for the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) axis I and II disorders [1]. Patients 
with a primary DSM-IV diagnosis of PD or a diagnosis of PD with 
or without agoraphobia, whose first panic attack occurred under 
acute cannabis intake, were included in the study. The induction 
of PD by cannabis was determined by the SCID and the anamnes-
tic interview. Patients with a secondary diagnosis of dysthymia or 
mild depression were not precluded from participation. Exclusion 
criteria included any other mental illness diagnosed by way of the 
SCID and severe chronic illness as determined by physical exami-
nations and routine laboratory tests as well as familiarity using the 
Trier Social Stress Test (TSST) [19]. Habitual cigarette smoking 
(≤10 cigarettes per day) and pharmaceutical treatment of PD, dys-
thymia, and mild depression were allowed to avoid significant se-
lection bias in the recruitment of study participants. Patients were 
matched individually for age and gender with HCs and a sample 
with PD patients without drug use.
The sample was collected from 2009 to 2013. The final patient 
sample consisted of 7 patients with a primary diagnosis of PD and 
7 patients with CIPD. The latter reported cannabis consumption 
on a rare to occasional basis (between 2 and 4 months no more 
than two times weekly) at the occurrence of the first panic attack. 
Patients with CIPD did not consume cannabis during the entire 
testing period. All patients were male in order to exclude the con-
founding effect of the menstrual cycle. The mean age at the onset 
of the PD was 29.17 years (SD = 7.36) in PD patients and 24.33 
years (SD = 7.45) in CIPD patients and the duration of the PD was 
4.78 (SD = 2.80) and 4.08 (SD = 4.30) years, respectively. Accord-
ing to the Panic and Agoraphobia Scale [20], most of the panic 
symptoms in both groups were rated as moderate to severe (PD: 
mean = 2.50 [SD = 0.84], CIPD: mean = 2.20 [SD = 0.84]). Three 
PD and 4 CIPD patients were diagnosed with a secondary diagno-
sis of mild depression. At the time of testing, 4 PD and 3 CIPD 
patients were on antidepressant medication (selective serotonin 
reuptake inhibitors [n = 3], serotonin norepinephrine reuptake in-
hibitors [n = 1], tricyclic antidepressants [n = 1], benzodiazepines 
[n = 2], monoamine oxidase inhibitors [n = 1], phytosedatives 
[n = 2], promethazine [n = 1], buspirone [n = 2], and quetiapine 
[n = 1]). All other participants were free of antidepressants or psy-
chotropic drugs. Furthermore, at the time of testing, the absti-
nence from cannabis consumption for the past 4 weeks was con-
firmed by a blood test. All participants were asked to refrain from 
cigarettes, alcohol, and coffee on the day prior to testing and the 
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testing day itself and these variables were controlled. Furthermore, 
not all participants were engaged in physical exercises.
Male HC participants (n = 7) had been recruited through news-
paper advertisements and were matched by age to the patient sam-
ples as described above. 
Sociodemographic and clinical sample characteristics are brief-
ly illustrated in Table 1. All participants gave written informed 
consent prior to participation. The current study was approved by 
the local Ethics Committee of the Medical Faculty of the Tech-
nische Universität Dresden, Germany (No. #EK7012006). 
Clinical Measures
Information concerning sociodemographic variables (gen-
der, age, smoking status) as well as medication intake was as-
sessed within a routine medical examination. To determine the 
severity of panic-related symptoms, the following questionnaires 
were applied: (1) the Panic and Agoraphobia Scale [20] for as-
sessing the global severity of PD. It consists of 13 questions an-
swered on a 5-point Likert scale. The internal consistency (Cron-
bach’s alpha) of the scale ranges between 0.88 and 0.89. The inter-
rater reliability is r = 0.78 (p < 0.05) [20]. (2) The Symptom 
Checklist [21] was used for patients to assess their physical and 
psychological impairment. It is one of the most commonly used 
procedures in clinical-psychological diagnostics [22]. The Symp-
tom Checklist is a 90-item questionnaire using a 5-point Likert 
scale to measure each item. (3) The Agoraphobic Cognitions 
Questionnaire [23] was implemented to self-evaluate the inten-
sity of panic and agoraphobic beliefs and catastrophic cognitions 
about panic. It consists of 14 items using a 5-point Likert scale 
ranging from 1 (thought never occurs) to 5 (thought always oc-
curs). Furthermore, it comprises two scales. Those scales relate 
to loss of control and physical concerns. (4) The Bodily Sensation 
Questionnaire [23] measures fear of bodily sensations that often 
occur during panic attacks. The total score of the Bodily Sensa-
tion Questionnaire is calculated as the average score of the 17 
items with a 5-point Likert scale regarding specific body sensa-
tions. (5) The Mobility Inventory [24] was used to self-assess pa-
tients’ agoraphobic avoidance behaviour in different situations. 
Ratings of situations had to be made for two conditions: when 
confronted with the situation alone and accompanied by another 
Table 1. Characteristics of the total sample 
Panic disorder 
patients
Cannabis-induced 
panic disorder  
patients
Healthy control 
subjects
F/χ2 p
Sociodemographics
Total, n 7 7 7
Age, yearsa 32.95 (9.04) 31.94 (8.40) 31.13 (8.57) 0.156 0.926
Smoking, %a 4 (57.14) 5 (71.43) 4 (57.14) 0.385 0.840
Depressive disordera 3 (42.86) 4 (57.14) 0 (0) 5.306 0.062
Antidepressant medication, %a 4 (57.14) 3 (42.86) 0 (0) 5.306 0.062
Clinical measures
PAS total score [0–52]a, c 27 (10.24) 25 (8.75) 2.29 (4.86) 12.523 0.000***
ACQ loss of control [0–4]a 0.57 (0.30) 1.06 (0.48) 0.57 (0.34) 4.324 0.095
ACQ physical concerns [0–4]a, d 1.52 (0.39) 1.48 (1.28) 0.33 (0.08) 8.753 0.007**
ACQ total score [0–4]b, e 0.89 (0.21) 1.10 (0.52) 0.32 (0.18) 8.336 0.005**
BSQ total score [0–4]b 1.40 (0.66) 1.96 (1.08) 0.79 (0.59) 2.968 0.087
MI alone [0–4]b 1.71 (1.41) 1.44 (1.30) 0.11 (0.12) 3.569 0.058
MI accompaniedb [0–4] 1.28 (1.15) 0.86 (0.79) 0.08 (0.11) 3.389 0.065
SCL-90 global severity index [0–>2.53]a, f 1.08 (0.65) 1.61 (0.05) 0.33 (0.22) 5.436 0.036*
Subjective level of distress
PASA stress index [–3.75 to 3.75]a –1.13 (1.98) –1.06 (0.09) –1.56 (2.03) 0.214 0.950
VAS mean [0–100]a 54.79 (7.30) 56.44 (6.81) 37.75 (0.18) 3.750 0.064
TSST-Responder, %a, g 2 (28.57) 4 (51.14) 7 (100) 7.308 0.026*
Mean (SD) are listed except where noted. PAS, Panic and Agoraphobia Scale; ACQ, Agoraphobic Cognitions Questionnaire; BSQ, 
Body Sensations Questionnaire; MI, Mobility Inventory; SCL, Symptom Checklist; PASA, Primary Appraisal Secondary Appraisal scale; 
VAS, Visual Analogue Scale. a Kruskal-Wallis test. b Univariate analysis of variance. c Post hoc analyses: PD > CIPD (p = 1.000), PD > 
HC (p ≤ 0.001), CIPD > HC (p = 0.001). d Post hoc analyses: PD > CIPD (p = 1.000), PD > HC (p = 0.017), CIPD > HC (p = 0.020). e Post 
hoc analyses: CIPD > PD (p = 0.966), CIPD > HC (p = 0.005), PD > HC (p = 0.042). f Post hoc analyses: CIPD > PD (p = 0.684), 
CIPD > HC (p = 0.049), PD > HC (p = 0.139). g Post hoc analyses: CIPD > PD (p = 0.651), HC > PD (p = 0.015), HC > CIPD (p = 0.213). 
* p ≤ 0.05; ** p ≤ 0.005; *** p ≤ 0.001.
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person. It consists of 27 questions that are answered on a 5-point 
Likert scale ranging from 1 (never avoided) to 5 (always avoided). 
All questionnaires have been reported to show good psychomet-
ric characteristics regarding reliability and validity. 
Trier Social Stress Test 
In order to test the hypothesis, the TSST [19], a well-estab-
lished, validated psychosocial stress paradigm, was applied. The 
TSST aims at inducing acute moderate psychosocial stress un-
der laboratory conditions [25] and has proven to be a reliable 
tool to evoke stress in anxiety disorders and drug dependence 
[26]. All participants were confronted individually with the 
standardized TSST protocol, which consists of a mock job in-
terview (5 min) and a subsequent mental arithmetic task 
(5 min) in front of a 2-person committee. Subjective levels of 
distress were determined by the Primary Appraisal Secondary 
Appraisal Questionnaire [27] prior to and a Visual Analogue 
Scale following the TSST. Testing was conducted between 
3 p.m. and 6 p.m. to avoid significant circadian differences in 
cortisol levels. Any eating or drinking was not allowed from at 
least 2 h before until the end of the testing session. It was en-
sured that all participants were confronted with identical pro-
cedures within the same setting.
Cortisol Sampling
Over the course of the TSST session, a total of 7 saliva samples 
per person were collected (10 min before and 0, 10, 20, 30, 40, and 
50 min after completion of the TSST) by way of Salivette swabs 
(Sarstedt, Nümbrecht, Germany) to ensure a fast and hygienic pro-
cedure. Samples were then kept frozen at –20  ° C before being as-
sayed for cortisol. For preparing the examination and producing a 
clear supernatant of low viscosity, samples were centrifuged at 
3,000 rpm for 5 min. For cortisol analysis, 50 µL were removed us-
ing a commercially available immunoassay with chemilumines-
cence detection. 
Statistical Analyses
Differences between groups in sociodemographic and clini-
cal measures were evaluated by using Kruskal-Wallis tests for 
non-parametric data and univariate analyses of variance (ANO-
VA) for normally distributed data. To check normal distribu-
tion of data, Shapiro-Wilk tests were conducted beforehand. 
For analysing group differences in the cortisol stress response, 
a 3 (group: PD patients, CIPD patients, HC participants) × 7 
(time: –10, 0, 10, 20, 30, 40, and 50 min) repeated-measures 
ANCOVA was accomplished. Baseline cortisol values (–10 
min) were added as covariates. Greenhouse-Geiser or rather 
Huynh-Feldt corrections were applied whenever the sphericity 
assumption was violated. In the event of significant results, LSD 
post hoc tests were applied to provide specific information on 
which results significantly differed from each other. Significant 
results of non-parametric data were reviewed by means of a 
Wilcoxon test.
The cortisol stress response following the TSST was defined 
as a baseline-to-peak increase in cortisol levels of at least 1.5 
nmol/L [28]. Regarding cortisol data, all available values were 
included in the assay as they were located within three standard 
deviations above and below the mean. Statistical analyses were 
conducted with the software Statistical Package for the Social 
Sciences for Windows, version 25 (SPSS Inc., Chicago, IL, USA).
Results
Clinical Measures
An overview of sociodemographic and clinical data is 
provided in Table 1. Groups did not differ significantly 
regarding age, smoking status, depressive disorders, and 
antidepressant medication (Table 1). Significant group 
differences were apparent in clinical measures of anxiety, 
depression as well as the Symptom Checklist global sever-
ity index (Table 1). HC participants consistently showed 
the lowest values across all questionnaires. While PD and 
CIPD patients rated their panic-related symptomatology 
as moderate to severe (PD: mean = 2.50; SD = 0.84, CIPD: 
mean = 2.20; SD = 0.84), substantially lower values were 
observable in HC participants (mean = 0.14; SD = 0.38). 
See Table 1 for detailed information on post hoc analyses.
TSST Cortisol Response
Baseline cortisol levels before the TSST did not differ 
statistically between groups (F2, 18 = 0.720, p = 0.500, n = 
21). 
ANCOVA results revealed a non-significant Green-
house-Geiser corrected main effect for time (F1.91, 32.49 = 
0.743, p = 0.478, n = 21, η2 = 0.042), a significant main 
effect of group (F2, 17 = 6.947, p = 0.006, n = 21, η2 = 0.45) 
as well as a significant time by group interaction effect 
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(F3.82, 32.49 = 8.463, p ≤ 0.001, n = 21, η2 = 0.499). The sal-
ivary cortisol course of the three study groups is illustrat-
ed in Figure 1. Post hoc analyses (LSD-corrected with α = 
5%) revealed significant group differences between PD 
and HC participants (p = 0.021). Descriptive differences 
were found between all groups (HC > PD [p = 0.021]; 
HC > CIPD [p = 0.596]; CIPD > PD [p = 0.743]).
Discussion
The current study aimed at examining the HPA axis 
activity of patients whose first panic attack was cannabis-
induced, when confronted with a threatening and uncon-
trollable psychosocial stressor.
Our data point out that CIPD patients display a pecu-
liar pattern of cortisol reactivity to psychosocial stress, 
compared to PD patients, whose PD did not develop fol-
lowing cannabis use. The present study revealed that pa-
tients with CIPD present blunted cortisol reactivity under 
standardized psychosocial stressor induction compared 
to healthy individuals. This is in line with cannabis users 
that displayed significantly lower cortisol responses than 
abstainers under a different psychosocial stress test [15]. 
The present results also stated that the cortisol reactivity 
in patients with CIPD is higher under standardized psy-
chosocial stressor induction compared to “regular” PD 
patients. This effect might be explicable by preclinical 
studies showing that the acute administration of Δ9-THC 
is associated with an increase in cortisol levels [17].
Baseline cortisol values did not differ significantly 
among groups. This matches findings of Petrowski et al. 
[8], who reported a blunted cortisol reactivity to the TSST 
with concurrent normal cortisol awakening responses in 
PD patients compared to HC participants. The similar 
baseline cortisol levels between PD patients and HC sub-
jects have already been reported elsewhere [29]. Interest-
ingly, baseline cortisol values (–10 min, 0 min) of CIPD 
patients were slightly higher than those of HC participants 
(and higher than PD patients), although this difference did 
not reach statistical significance (Fig. 1). This fact accounts 
for the idea of a higher reactivation of the HPA axis com-
pared to PD patients and hence elevated cortisol levels in 
resting conditions without stress exposure in substance-
consuming people as shown by Armario [30].
The ANCOVA revealed a pattern of cortisol hypore-
sponsiveness in both, PD and CIPD patients compared 
with HC subjects. In terms of the comparison between 
PD and HC subjects, our findings are in keeping with pre-
vious findings of a cortisol hyporesponse in patients with 
PD [8–10, 29, 30, 32]. As cortisol levels of CIPD patients 
were located between those of PD patients and HC sub-
jects, our assumption of HPA axis reactivity in CIPD pa-
tients balancing between hypocortisolism and cortisol re-
activity of healthy people when exposed to the TSST can 
be confirmed.
Regarding the cortisol course of CIPD patients, our 
results match previous findings of a reduced HPA axis 
activity after the consumption of cannabis [14, 33, 34]. 
However, it contradicts findings of regular or increased 
HPA axis activation following cannabis consumption 
[13, 14, 35, 36]. Current results are most likely compara-
ble to van Leeuwen et al. [15] even though not the same 
psychosocial stress paradigm was applied. Although cur-
rent differences between CIPD patients and HC partici-
pants did not reach statistical significance, results of both 
studies point in the same direction of an HPA hypoacti-
vation in CIPD patients when confronted with a psycho-
social stressor compared to HCs. 
Compared with PD patients, CIPD patients showcased 
a slightly heightened cortisol reactivity. This could be due 
to the fact that in study participants self-reported canna-
bis consumption took only place on a rare to occasional 
basis excluding habituation processes to cannabis as those 
described by Ranganathan et al. [14]. Still it remains re-
markable that cortisol response patterns to psychosocial 
stress clearly differ between CIPD and PD, indicating that 
cannabis consumption as an aetiological factor for PD has 
a considerable influence on psychoneuroendocrine func-
tioning and HPA axis activity. PD in CIPD is primarily 
chemically induced, whereas the development of PD in 
the PD patient group has different causes, but not sub-
stance consumption. As psychoneuroendocrine patterns 
differ between groups, results raise the question of wheth-
er the manifestation of PD differs, depending on its aetio-
logical origin. This and further questions would have to 
be addressed in future investigations, since this study 
must be considered a pilot study that emphasizes the need 
for deeper exploration of HPA axis activity in CIPD pa-
tients.
Since the three groups did not differ significantly re-
garding age and smoking status, these variables can be 
excluded as significant confounding factors. The same 
applies to the comorbidity of depression and antidepres-
sant medication, which were balanced between PD and 
CIPD patients and did not differ significantly from the 
values of HC subjects. Furthermore, a previous study 
comparing PD patients to patients with a mild major de-
pressive disorder revealed a cortisol hyporesponsiveness 
in PD patients in response to the TSST. Additional analy-
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ses showed no impact of comorbid depressiveness on the 
cortisol stress response. Major depressive disorder pa-
tients did not differ in the hormonal stress response nei-
ther compared to the healthy participants nor to the PD 
patients [37]. Additionally, patients with moderate to se-
vere major depressive disorder are rather linked to height-
ened HPA axis activity and cortisol hyperresponsiveness 
to stressors [38, 39]. Higher cortisol levels after the TSST 
during the recovery period have also been confirmed in a 
meta-analysis on depression and cortisol response to psy-
chological stress [40]. Therefore, the blunted cortisol re-
sponse cannot be reasonably explained by comorbid de-
pressive disease. 
However, the present study is limited by the small size 
of the total sample. This is due to the rare condition of 
CIPD patients in clinical practice. Another limitation is 
the lack of chemical analyses quantifying blood levels of 
THC in the past and at the time of the first panic attack. 
The exact analysis of THC levels would allow for more 
differentiated analyses. However, abstinence from can-
nabis consumption in the previous month was confirmed 
by a blood test. Furthermore, all participants were male 
to exclude the confounding effect of the menstrual cycle. 
While women in the luteal phase of the menstrual cycle 
and men show similar salivary cortisol levels after psy-
chosocial stress, respective hormone levels during the fol-
licular phase of the menstrual cycle tend to be lower [41]. 
For further research, sex-related HPA axis response pat-
terns should be examined in patients with CIPD.
Future research should additionally collect corticotro-
pin-releasing hormone and plasma adrenal corticotropin 
data as well as blood cortisol samples to more precisely 
determine the differences in HPA axis activity between 
PD and CIPD patients.
Nonetheless, current results provide evidence for an 
enhanced HPA axis activity upon laboratory stress induc-
tion in CIPD compared to PD patients. This study is the 
first to exhibit a distinctive pattern of cortisol responsive-
ness to psychosocial stress in CIPD patients and thus em-
phasizes the importance of aetiological factors of PD for 
psychoneuroendocrine functioning within the disease. 
Besides, data provide further support to previous findings 
of hypocortisolism in PD patients compared to HC sub-
jects. Depressiveness had no impact on the cortisol re-
sponse in neither group. Hopefully, current results en-
courage further examinations of CIPD patients, for gain-
ing an enhanced understanding of the complexity of their 
psychoneuroendocrine functioning.
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